Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Bifidobacteria, a genus of beneficial gut bacteria, has been investigated for its potential role in supporting cognitive function and possibly alleviating symptoms related to Alzheimer's Disease (AD). Scientific interest stems from the "gut-brain axis," a concept describing the bidirectional communication between the gut microbiota and the central nervous system. Research indicates that individuals with Alzheimer's often exhibit altered gut microbiota composition, including reduced levels of Bifidobacteria. Preclinical animal studies have shown that supplementation with Bifidobacteria can improve cognitive performance and reduce neuroinflammation and amyloid-beta accumulation, which are hallmarks of Alzheimer's pathology. However, clinical evidence in humans remains limited. A few small randomized controlled trials and pilot studies suggest that probiotic mixtures containing Bifidobacteria (often combined with Lactobacilli) may have modest effects on cognitive function or certain biomarkers in Alzheimer's patients. For example, a 2016 study by Akbari et al. found improved Mini-Mental State Examination (MMSE) scores in AD patients after 12 weeks of probiotic supplementation, but this effect was not solely attributable to Bifidobacteria. The exact mechanisms remain under investigation, but proposed actions include modulation of systemic inflammation, oxidative stress reduction, and maintenance of gut barrier integrity. Overall, while there is scientific rationale and early evidence supporting Bifidobacteria's use in Alzheimer's Disease, robust clinical data are lacking, and more high-quality trials are needed. Its use is not traditional but based on emerging science.

More about Bifidobacteria
More about Alzheimer's Disease

Other ingredients used for Alzheimer's Disease

Other health conditions supported by Bifidobacteria

Products containing Bifidobacteria